Human papillomavirus E2 protein (HPV E2)

The Human papillomavirus E2 protein is a multifunctional viral regulatory factor essential for the HPV life cycle. E2 contains three domains: an N-terminal protein interaction domain, a flexible central hinge region, and a C-terminal DNA-binding and dimerization domain[2][5][8]. E2 binds specifically and cooperatively to palindromic DNA sequences in the viral long control region, regulating transcription of viral oncogenes, initiating viral DNA replication by recruiting the E1 helicase, and tethering viral genomes to host chromatin for maintenance during cell division[2][3][4][5][8][10]. In addition to orchestrating viral gene expression, E2 modulates host alternative splicing and suppresses innate immune responses—including the cGAS-STING and JAK-STAT pathways—facilitating viral persistence and immune evasion[4][7]. Loss or disruption of E2 expression, typically via viral DNA integration, is common in HPV-driven cancers, distinguishing benign from malignant progression. The E2 protein is being explored as a therapeutic target for antiviral strategies and as a biomarker to assess HPV integration status and oncogenic risk[2][4][7]. No drugs directly targeting E2 have received clinical approval, though research into E2 inhibitors is ongoing.

Other names

E2 proteinPapillomavirus E2 proteinRegulatory protein E2

Inhibition of E2-DNA binding (proposed for experimental therapeutics); Disruption of E2-E1 interaction (suggested in preclinical work); Modulation of E2-mediated transcriptional regulation